Loading…
Titan Biotech (BSE 524717)₹366.40+3.94%Specialty Chemicals
At the end of the Jun 2026 quarter, Titan Biotech's shareholders were: promoters 55.80%, DIIs 0.01%, public 44.19%. Promoter holding is unchanged on the quarter. It had 18,674 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 55.89% | 55.89% | 55.89% | 55.89% | 55.89% | 55.89% | 55.89% | 55.89% | 55.80% | 55.80% | 55.80% | 55.80% |
| DIIs | 0.00% | 0.00% | 0.23% | 0.00% | 0.00% | 0.00% | 0.01% | 0.03% | 0.03% | 0.03% | 0.03% | 0.01% |
| Public | 44.11% | 44.11% | 43.88% | 44.11% | 44.11% | 44.11% | 44.10% | 44.08% | 44.17% | 44.17% | 44.17% | 44.19% |
| Number of shareholders | 17,458 | 15,759 | 15,879 | 15,853 | 15,703 | 16,041 | 16,373 | 16,331 | 16,043 | 16,370 | 17,460 | 18,674 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Titan Securities Ltd | Promoter | 33.56% | 0.00 |
| Tanita Leasing & Finance Limited | Promoter | 9.54% | 0.00 |
| Investor Education And Protection Fund Author | Public | 9.53% | −0.07 |
| Connoisseur Management Services Private Limit | Promoter | 6.75% | 0.00 |
| Manish Goel | Public | 2.83% | 0.00 |
| Titan Biotech Limited Unclaimed Suspense Dema | Public | 2.38% | −0.15 |
| Suresh Chand Singla | Promoter | 1.27% | 0.00 |
| Manju Singla | Promoter | 0.85% | 0.00 |
| Madhu Gupta | Promoter | 0.80% | 0.00 |
| Raja Singla | Promoter | 0.74% | 0.00 |
| Supriya Singla | Promoter | 0.66% | 0.00 |
| Udit Singla | Promoter | 0.61% | 0.00 |
| Shivom Singla | Promoter | 0.43% | 0.00 |
| Naresh Kumar Singla | Promoter | 0.42% | 0.00 |
| Naresh Kumar Singla Huf | Promoter | 0.12% | 0.00 |
| Ravinder Gupta | Promoter | 0.00% | 0.00 |
Promoters held 55.80% of Titan Biotech at the end of the Jun 2026 quarter, down 0.09 percentage points from 55.89% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held no reported stake and domestic institutions (DIIs) held 0.01% (down 0.02 percentage points from 0.03% a quarter earlier).
Titan Biotech had 18,674 shareholders at the end of the Jun 2026 quarter, against 16,331 a year earlier.
Investor Education And Protection Fund Author (Public) held 9.53% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.